Lv4
734 积分 2024-09-26 加入
Discovery and Optimization of Orally Bioavailable Heterobifunctional Degraders of KAT2A/B for the Treatment of Cancer
1天前
待确认
Structural insights into IL-31 signaling inhibition by a neutralizing antibody
21天前
已完结
Anti-tumor effects of Skp2 inhibitor AAA-237 on NSCLC by arresting cell cycle at G0/G1 phase and inducing senescence
1个月前
已完结
Targeting the Skp2–Cks1 protein–protein interaction: structures, assays, and preclinical inhibitors
1个月前
已完结
Dancing with KAT6A: Current advances and therapeutic potential in oncology of KAT6A inhibitors
2个月前
已关闭
Dancing with KAT6A: Current advances and therapeutic potential in oncology of KAT6A inhibitors
2个月前
已关闭
Discovery of JAK2V617F mutant specific allosteric inhibitors for the treatment of myeloproliferative neoplasms
2个月前
已完结
Dancing with KAT6A: Current advances and therapeutic potential in oncology of KAT6A inhibitors
2个月前
已关闭
Evaluation of Enzyme Inhibitors in Drug Discovery
2个月前
已完结
ZE74-0282 is a novel JH2 domain JAK2 inhibitor with promising pre-clinical activity in JAK2 V617F mutant diseases
3个月前
已关闭
皖公网安备34019202002308
